Results from two studies presented at ESMO 2019 in patients with locally advanced resectable gastric cancer - the PRODIGY and RESOLVE trials - demonstrate the benefit of perioperative chemotherapy regimens as reported by Prof. Ian Chau from The Royal Marsden Hospital NHS Foundation Trust, Sutton, UK. The presented data may have a significant impact on clinical practice, especially in Asian countries.
Patients with advanced gastric cancer benefit from perioperative chemotherapy in two studies
